# Adversarial re-verification verdict: pleomorphic_xanthoastrocytoma.md

## 1. DOSE LEAK
None. Grepped all digits in the file: only WHO/CNS grade numbers (grade 2, grade 3, "grade 2 to 3"),
"V600E", and "12th ed." No mg, mg/m2, AUC, Gy, cycle counts, or % anywhere.

## 2. UNGROUNDED / MISLABELLED CLAIMS
Reviser fixed the three bullets flagged in the prior verdict - verified against DeVita: those
passages ("no clear consensus regarding adjuvant radiation," "higher radiotherapy doses are
warranted," "no optimal chemotherapeutic regimen... reserved for young children... disease
stabilization considered success") are indeed ganglioglioma-section-specific in DeVita (under the
GANGLIOGLIOMAS heading, Radiation Therapy/Chemotherapy subsections), and are now correctly re-scoped
to "DeVita's discussion of the closely related ganglioglioma group" with the PXA-extrapolation
hedge. Good fix, confirmed by direct grep/read of the DeVita text around the GANGLIOGLIOMAS heading.

**But the identical mis-scoping pattern survives, unfixed, in the Surgery section** (two bullets):

- Bullet 1: "mirroring DeVita's statement for astroglial-variant low-grade gliomas that gross total
  resection provides long-term tumor control in the great majority of cases and is the preferred
  treatment for both newly diagnosed and recurrent tumors."
- Bullet 2: "Complete resection is associated with a very favorable long-term outcome, while the
  degree of anaplasia... is a key determinant of prognosis, per the same DeVita discussion of this
  tumor group."

DeVita's actual sentences ("Gross total resection provides long-term tumor control in >95% of
gangliogliomas and is the preferred treatment for newly diagnosed and recurrent tumors"; "complete
resection is associated with a very favorable long-term survival... The degree of anaplasia
determines the prognosis") sit under the GANGLIOGLIOMAS heading and are grammatically scoped to
"gangliogliomas," not restated anywhere for the broader "astroglial-variant" group that includes
PXA (the only group-wide sentence DeVita gives is the taxonomic one used correctly in the Overview
section: "are considered astroglial variant forms of low-grade gliomas... do not typically invade
the normal brain... surgery alone is often curative"). Attributing the quantitative GTR/prognosis
statements to "DeVita's statement for astroglial-variant low-grade gliomas" / "the same DeVita
discussion of this tumor group" overstates scope, exactly the class of error already fixed for
Radiotherapy/Systemic therapy, and these two bullets carry no "(general oncology standard, not from
DeVita's section on this disease)" hedge. Net effect: mis-attributed to DeVita (scope overreach),
not a fabrication (the underlying clinical claim is uncontroversial and is DeVita-sourced, just
ganglioglioma-scoped rather than group-wide).

The third Surgery bullet ("Repeat resection at recurrence...") is correctly hedged and correctly
sourced to the cerebellar-astrocytoma section - verified against DeVita's cerebellar pilocytic
astrocytoma Radiation Therapy paragraph ("repeat resection is a reasonable treatment option if a
majority of the tumor can be removed"). No issue there.

BRAF/MEK section re-verified clean against DeVita's "BRAF, MEK, and NTRK" subsection: basket-trial
detail (responses in a minority of patients [DeVita: 25% of 24 patients, correctly generalized down,
no number leak], duration >1 year overall / >2 years in xanthoastrocytoma), pediatric/young-adult
frequency, "long-lasting responses," small-series BRAF+MEK combination benefit, and the CNS-
penetration caveat all match DeVita's text closely and are correctly attributed (one of the few
places DeVita's CNS chapter names xanthoastrocytoma directly, so no relabeling was needed here).
Temozolomide, seizure-management, and monitoring bullets remain correctly hedged as before, no
change needed.

## 3. CITATION
Present: "Sources: DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology, 12th
ed. NCCN Guidelines (CNS Cancers) where noted above." Name + edition only, no page numbers. Compliant.

## 4. VERDICT: ISSUES (not CLEAN, not ready for R1 re-review as-is)

The reviser's "Clean" report is incorrect: it fixed the three bullets R1/adversarial flagged before,
but missed that the identical unhedged ganglioglioma-to-PXA scope overreach is still present in the
Surgery section's first two bullets. Fix required before re-review: relabel those two bullets to
attribute the GTR/prognosis statistics to "DeVita's discussion of the closely related ganglioglioma
group" and append the standard "(general oncology standard, not from DeVita's section on this
disease)" hedge for the PXA extrapolation, consistent with how the rest of the file now handles
ganglioglioma-sourced content. Everything else (dose-free check, citation format, BRAF/MEK grounding,
TMZ/seizure/monitoring hedges) is clean.
